Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 120 clinical trials
None
Trial of Bortezomib Cytarabine and Dexamethasone in Mantle Cell Lymphoma

The purpose of this study is to determine whether bortezomib, cytarabine, and dexamethasone are effective in the treatment of relapsed or refractory mantle cell lymphoma after 1 to 3 lines of

neutrophil count
refractory mantle cell lymphoma
renal function tests
dexamethasone
cytarabine
  • 8 views
  • 21 Jan, 2021
None
TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib

> Proteasome inhibition with bortezomib appears to be a promising treatment strategy to restore chemo-sensitivity via EZH2 stabilisation. This study aims at improving response rates in

hydroxyurea
remission
consolidation therapy
neoadjuvant therapy
lymphoma
  • 0 views
  • 24 Jan, 2021
  • 1 location
None
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC

The hypothesis of this pilot trial is that administration of bortezomib will inhibit NHEJ in metastatic TNBC leading at the time of disease progression to metastases that are HR-deficient and

cish
metastasis
core needle biopsy
taxane
immunostimulant
  • 1 views
  • 17 Oct, 2021
  • 1 location
None
CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma

Bortezomib and Dexamethasone in patients with Previously Treated Multiple Myeloma.

platelet count
dexamethasone
neutrophil count
bortezomib
  • 18 views
  • 24 Jan, 2021
  • 1 location
None
Ibrutinib Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL IPI 2

The ImbruVeRCHOP-Trials is an Investigator-initiated, single-arm, multi-center, prospective, open phase I/II trial to evaluate the efficacy and feasibility of Ibrutinib and Bortezomib in the

prednisone
renal function
cyclophosphamide
b-cell lymphoma
ibrutinib
  • 4 views
  • 28 Jan, 2021
  • 2 locations
None
Metformin Nelfinavir and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

This phase I trial studies the side effects and best dose of metformin and nelfinavir in combination with bortezomib in treating patients with multiple myeloma that has come back or does not

immunoglobulin a
nelfinavir
electrophoresis
immunomodulatory imide drug
monoclonal antibodies
  • 0 views
  • 13 Oct, 2021
  • 2 locations
None
Bortezomib and Temozolomide in Recurrent Glioblastoma With Unmethylated MGMT Promoter (BORTEM-17)

This phase IB/II trial is designed to investigate the safety and survival benefits for patients with recurrent glioblastoma with unmethylated MGMT promoter treated with Bortezomib and

platelet count
temozolomide
recurrent tumor
recurrent glioblastoma
corticosteroids
  • 48 views
  • 04 Sep, 2021
  • 2 locations
None
Daratumumab Ixazomib & Dexamethasone or Daratumumab Bortezomib & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

This phase II trial studies how well daratumumab, ixazomib, and dexamethasone with or without bortezomib work in treating patients with newly diagnosed multiple myeloma. Immunotherapy with

immunoglobulin a
vasectomy
calcium
monoclonal antibodies
bone marrow procedure
  • 0 views
  • 26 Jan, 2021
  • 1 location
None
Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

own to treat some blood cell cancers. Objectives To test the safety and efficacy of the drug combination of bortezomib and clofarabine.

solid neoplasm
neutrophil count
solid tumour
chemotherapy regimen
bisphosphonate
  • 25 views
  • 28 Nov, 2021
  • 1 location
None
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

bortezomib (refractory). Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

platelet count
ixazomib
electrophoresis
neutrophil count
monoclonal protein
  • 2 views
  • 31 Oct, 2021
  • 3 locations